Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Post-transplant survival boosted by brentuximab vedotin in lymphoma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 1905
Rating:

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Moskowitz talks to ecancertv at ASH 2014 about the findings of a phase III trial which compared brentuximab vedotin (BV), an antibody targeting the CD30 protein on Hodgkin lymphoma cells, with placebo in 327 patients at risk of post-transplant disease progression.

Watch the press conference or read the news story for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation